Conversely, the negative correlation in GBM、LGG and other cancer types implies that DDX17 might contribute to immune evasion, suggesting that targeting DDX17 could improve the efficacy of immune checkpoint inhibitors in these cancers. Here, DDX17 is linked to glioblastoma.